MIRXES-B (02629) has announced that the company has entered into a memorandum of understanding with Apollo Health and Lifestyle Limited (AHLL), a wholly-owned subsidiary of Apollo Hospitals Enterprise Limited (Apollo), to pursue a strategic collaboration. The partnership aims to jointly develop and commercialize advanced early cancer detection solutions in India and neighboring countries. Subject to achieving agreed objectives and receiving approval from respective boards, a joint venture is expected to be established in India. Based on the intellectual property, clinical pipelines, research and development, clinical trial infrastructure, and commercial channels to be contributed by both MIRXES and Apollo, the joint venture's equity value is anticipated to be no less than $50 million. As a leading healthcare provider in Asia, Apollo and AHLL are widely recognized in South Asia and the Middle East for their advanced medical services and are committed to enhancing their position as global leaders in preventive oncology and disease management. Apollo is also renowned as a top-tier cancer treatment institution in India, dedicated to becoming a key player in global early disease detection and prevention through innovative methods. This collaboration will combine Mirxes' breakthrough miRNA and multi-omics technologies, core products (GASTROClear and LUNGClear), and its maturing clinical pipeline—which includes established pipelines for colorectal, liver, and breast cancers, as well as the CADENCE multi-cancer test—with Apollo's extensive clinical expertise, nationwide hospital network, and community healthcare service capabilities. The partnership aims to achieve an ambitious vision: detecting cancer early, intervening when it is curable, and transforming treatment outcomes for millions of patients. The collaboration is designed to scale the commercialization and market adoption of these solutions, thereby expanding access to early disease screening in the region. The board of directors believes that the proposed strategic cooperation with Apollo represents a significant synergistic opportunity that aligns with the long-term strategic goals of the group. By leveraging Apollo's extensive hospital network and large patient base, the partnership is expected to facilitate the widespread adoption of the group's early cancer detection solutions. This initiative will help address existing gaps in India's healthcare system, particularly in the areas of early detection and disease screening. The board further views this collaboration as a platform for the group's future business expansion in India, enabling earlier clinical interventions and improving patient outcomes.
Comments